Home » Newsletters » BioWorld Asia

BioWorld Asia

July 5, 2000

View Archived Issues

Modex Raises US$103M In IPO In Switzerland To Fund Programs

Pharmagene Plans To Go Public In London, Says Time Is Right

Research Shows Strategies For Malaria Could Be Off Target

Mologen Raises EUR12.45M For Phase III Cancer Trials

European Stem Cell Debate Provokes Deeper Questions

Metris Raises #11M Privately For Work On Women's Health

Transghne, IntroGene Collaborate To Produce Adenoviral Vectors

Molecular Engine Formed To Exploit Novel Cancer Approach

IDM Issued U.S. Patent Covering Cell Preparation

Other News To Note

Oxford BioMedica Demonstrates Utility Of LentiVector Technology

Memorec Seeks Up To US$15M For Integrated Genomics Work

Australian Consortium Awarded $16M By NIH For AIDS Vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...